TY - JOUR
T1 - Protocolo EPICOVID19
T2 - Pesquisas sorológicas repetidas de anticorpos SARS-CoV-2 no Brasil
AU - Hallal, Pedro Curi
AU - Barros, Fernando C.
AU - Silveira, Mariângela Freitas
AU - de Barros, Aluísio Jardim Dornellas
AU - Dellagostin, Odir Antonio
AU - Pellanda, Lúcia Campos
AU - Struchiner, Claudio José
AU - Burattini, Marcelo Nascimento
AU - Hartwig, Fernando Pires
AU - Menezes, Ana Maria Baptista
AU - Horta, Bernardo Lessa
AU - Victora, Cesar Gomes
N1 - Funding Information:
To IBOPE, the company responsible for data collection. This work is funded by the Brazilian Ministry of Health. The funder had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Publisher Copyright:
© 2020, Associacao Brasileira de Pos - Graduacao em Saude Coletiva. All rights reserved.
PY - 2020
Y1 - 2020
N2 - The first case of COVID-19 was reported in China in December 2019, and, as the virus has spread worldwide, the World Health Organization declared it a pandemic. Estimates on the number of COVID-19 cases do not reflect it real magnitude as testing is limited. Population based data on the proportion of the population with antibodies is relevant for planning public health policies. We aim to assess the prevalence of SARS-CoV-2 antibodies, presence of signs and symptoms of COVID-19, and adherence to isolation measures. A random sample comprising 133 sentinel cities from all states of the country will be selected. Three serological surveys, three weeks apart, will be conducted. The most populous municipality in each intermediate region of the country, defined by the Brazilian Institute of Geography and Statistics, was chosen as sentinel city. In each city, 25 census tracts will be selected, and 10 households will be systematically sampled in each tract, totaling 33,250 participants. In each household, one inhabitant will be randomly selected to be interviewed and tested for antibodies against SARS-CoV-2, using WONDFO SARS-CoV-2 Antibody Test. By evaluating a representative sample of Brazilian sentinel sites, this study will provide essential information for the design of health policies.
AB - The first case of COVID-19 was reported in China in December 2019, and, as the virus has spread worldwide, the World Health Organization declared it a pandemic. Estimates on the number of COVID-19 cases do not reflect it real magnitude as testing is limited. Population based data on the proportion of the population with antibodies is relevant for planning public health policies. We aim to assess the prevalence of SARS-CoV-2 antibodies, presence of signs and symptoms of COVID-19, and adherence to isolation measures. A random sample comprising 133 sentinel cities from all states of the country will be selected. Three serological surveys, three weeks apart, will be conducted. The most populous municipality in each intermediate region of the country, defined by the Brazilian Institute of Geography and Statistics, was chosen as sentinel city. In each city, 25 census tracts will be selected, and 10 households will be systematically sampled in each tract, totaling 33,250 participants. In each household, one inhabitant will be randomly selected to be interviewed and tested for antibodies against SARS-CoV-2, using WONDFO SARS-CoV-2 Antibody Test. By evaluating a representative sample of Brazilian sentinel sites, this study will provide essential information for the design of health policies.
KW - COVID19
KW - Epidemiology
KW - Serological survey
UR - http://www.scopus.com/inward/record.url?scp=85090180586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090180586&partnerID=8YFLogxK
U2 - 10.1590/1413-81232020259.25532020
DO - 10.1590/1413-81232020259.25532020
M3 - Article
C2 - 32876244
AN - SCOPUS:85090180586
SN - 1413-8123
VL - 25
SP - 3573
EP - 3578
JO - Ciencia e Saude Coletiva
JF - Ciencia e Saude Coletiva
IS - 9
ER -